Drug Profile
Research programme: cancer therapy - Shire BioChem
Alternative Names: cancer therapy research programme - Shire BioChemLatest Information Update: 17 May 2004
Price :
*
At a glance
- Originator Shire BioChem
- Class
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 May 2004 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 30 Apr 2002 Preclinical trials in Cancer in Canada (unspecified route)